Scientific Posters , Phase I , Formulation Development

Human Mass Balance Study of [14C]-CORT125281: Characterizing Absorption, Metabolism and Excretion Following Oral Administration

22 October 2026

Home
Resources
Human Mass Balance Study of [14C]-CORT125281: Characterizing Absorption, Metabolism and Excretion Following Oral Administration

Overview

This ISSX 2026 poster presents the results of a Phase 1 human mass balance study evaluating[14C]-CORT125281, an investigational therapy in development for the treatment of prostate cancer in combination with enzalutamide.

Download the ISSX 2026 poster to learn how this open-label study assessed the recovery, pharmacokinetics, metabolism and excretion of radiolabelled CORT125281 following a single oral dose administered to healthy male subjects.

Download

First name

Last name

Company name

Job title

Phone

City

Country

Do you want to opt into updates on news and info?

Yes, please opt me in for updates

No, I don't wish to receive updates

Date

22 October 2026

Translational Pharmaceutics® for integrated drug development

We can apply Translational Pharmaceutics® to your next drug program, whether your goal is getting to first-in-human trials faster, optimizing your drug product further coming out of Phase I studies, or for enabling more successful human ADME programs.

Translational Pharmaceutics® Contact Us

How does Translational Pharmaceutics work?

Human Mass Balance Study of [14C]-CORT125281: Characterizing Absorption, Metabolism and Excretion Following Oral Administration

Download

Date

Share

Translational Pharmaceutics® for integrated drug development

Learn more about Translational Pharmaceutics®: